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Abstract
Cancer patients are at increased risk of venous thromboembolism due to a range of factors directly related to their
disease and its treatment. Given the high incidence of post-surgical venous thromboembolism in cancer patients
and the poor outcomes associated with its development, thromboprophylaxis is warranted. A number of evidence-
based guidelines delineate anticoagulation regimens for venous thromboembolism treatment, primary and second-
ary prophylaxis, and long-term anticoagulation in cancer patients. However, many give equal weight to several dif-
ferent drugs and do not make specific recommendations regarding duration of therapy. In terms of their efficacy
and safety profiles, practicality of use, and cost-effectiveness the low-molecular-weight heparins are at least com-
parable to, and offer several advantages over, other available antithrombotics in cancer patients. In addition, data
are emerging that the antithrombotics, and particularly low-molecular-weight heparins, may exert an antitumor
effect which could contribute to improved survival in cancer patients when given for long-term prophylaxis. Such
findings reinforce the importance of thromboprophylaxis with low-molecular-weight heparin in cancer patients.
Introduction
Venous thromboembolism (VTE), comprising deep vein
thrombosis (DVT) and pulmonary embolism (PE), is
one of the principal causes of morbidity and mortality
in surgical patients [1]. The development of post-surgi-
cal VTE is associated with significantly higher rates of
hospital readmission, VTE recurrence, and a greater
than 3-fold increase in mortality [2]. Cancer patients are
at additional risk of VTE [3], and following cancer sur-
gery VTE is the most common cause of death at 30
days [4].
The probability of diagnosing concomitant cancer is
up to 10-times greater for cases of idiopathic VTE com-
pared with those where the pre-disposing risk factor is
known [5,6]. In a recent systematic review, the reported
12-month prevalence for cancer following VTE was
10.0% (95% confidence interval [CI]: 8.6-11.3) in patients
with idiopathic VTE compared with 2.6% (95% CI: 1.6-
3.6) in those with a provoked VTE [7]. Overall, around
10-20% of all non-cancer patients who present with
idiopathic VTE develop cancer over the following 3
years [8]. The association between VTE and cancer is so
pronounced that some researchers have argued that
patients with idiopathic VTE be screened for occult can-
cer [7].
The risk of VTE in cancer patients varies according to
disease-specific factors such as the location, stage, and
type of the malignancy [3,9]. In addition, cancer patients
typically present with a number of co-morbid conditions
that predispose individuals to thrombosis, such as older
age and frequent hospitalization [10,11]. Cancer patients
u n d e r g o i n gs u r g e r yh a v eu pt ot w i c et h er i s ko fD V T
and three-times the risk of PE as non-cancer patients
undergoing similar operations [12,13]. VTE risk is
further increased by cancer therapies, with significant
increases in VTE in cancer patients treated with chemo-
and hormonal-therapy [11,14,15]. There is, therefore, a
clear need for thromboprophylaxis in surgical cancer
patients which is supported by current guidelines
[1,16-19]. This review summarizes the relative merits of
the low-molecular-weight heparins (LMWHs) and the
other principal anticoagulants used for thromboprophy-
laxis in this high-risk population.
Pathophysiology of VTE and cancer
Although the relationship between cancer and VTE was
first recognized almost 150 years ago [20], the molecular
basis of this association has only recently been
* Correspondence: pacorobertuab@cs.com
Department of Medicine, Division of Hematology/Oncology, Comprehensive
Cancer Center, University of Alabama at Birmingham, 1802 6th Avenue
South, NP CC-2555, Birmingham, AL 352943300, USA
Robert Journal of Hematology & Oncology 2010, 3:3
http://www.jhoonline.org/content/3/1/3 JOURNAL OF HEMATOLOGY
& ONCOLOGY
© 2010 Robert; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.investigated. Studies have shown a complex pathophy-
siology involving perturbation of multiple components
within the coagulation and fibrinolytic pathways. The
association between cancer and VTE works both ways,
with cancer inducing a hypercoagulable state and the
pro-thrombotic changes in turn facilitating cancer
growth and metastasis [21]. Cancer cells have been
shown to aberrantly express several components
involved in coagulation. For example, tissue factor, a key
activator of the coagulation cascade, is expressed on
endothelial cells, monocytes and, most importantly, on
tumor cells themselves and is thought to play a pivotal
role in cancer-induced hypercoagulability [21]. In addi-
tion, cancerous cells can produce a cysteine proteinase,
termed cancer procoagulant, which directly cleaves fac-
tor X to Xa leading to the generation of thrombin and
thrombus formation [22]. von Willebrand factor (vWF)
promotes platelet adhesion during thrombus formation
and elevated vWF levels have been detected in various
cancers [23]. Aberrant expression of glycoprotein IIb/
IIIa receptors, which are involved in platelet activation
and adhesion, and serve to promote and stabilize
thrombi, is also observed on tumor cells [24].
Cancer is also associated with disturbances of the
fibrinolytic system. Plasmin, which breaks down fibrin
clots, is produced from its precursor molecule plasmino-
gen in response to plasminogen activator or urokinase-
type plasminogen activator, and is inhibited by plasmi-
nogen activator inhibitor [25]. However, deregulation of
these factors is observed in cancer patients, resulting in
disruptions to the normal process of clot lysis [25]. Can-
cer patients may, therefore, possess abnormal expression
of a number of factors which are crucial for normal
hemostasis, resulting in a general state of hypercoagul-
ability. In addition to their hemostatic effects, many of
these molecules are also involved in other physiological
systems, most notably angiogenesis. Many components
of the coagulation cascade are also involved in tumor
neovascularization, tumor cell growth, and metastasis
[21]. This has particular relevance for the anti-neoplastic
effects of the various antithrombotics as discussed later.
Thromboprophylaxis in cancer patients
Several evidence-based guidelines are available that
delineate appropriate anticoagulation regimens for VTE
treatment, primary and secondary prophylaxis, and
long-term anticoagulation in cancer patients [1,16-19].
However, despite the existence of these guidelines and
the high-risk of VTE in cancer patients, up to 75% of
cancer patients do not receive appropriate prophylaxis
[26]. Cancer patients are significantly less likely than
non-cancer patients to have received thromboprophy-
laxis prior to DVT occurrence [27]. In a sub-group ana-
lysis of the Epidemiologic International Day for the
Evaluation of Patients at Risk for Venous Thromboem-
bolism in the Acute Hospital Care Setting (ENDORSE)
[28] worldwide study comprising 1,767 cancer patients
undergoing abdominal, gynecological or urological sur-
gery, 27.7% of patients did not receive appropriate
thromboprophylaxis [29].
The use of thromboprophylaxis in cancer patients is
complicated by the fact that although they are at an
increased risk of VTE, they are also at an increased risk
of bleeding [30,31]. Given that the risk of VTE out-
weighs the risk of bleeding in most cancer patients
[30,31], the use of antithrombotic agents which provide
stable anticoagulation while minimizing bleeding com-
plications is especially important in this high-risk popu-
lation. In addition, the available guidelines are not
always consistent in their recommendations, often give
several drugs equally weighted recommendation, and do
not always specify the appropriate treatment duration
[1,16-19]. Given these ambiguities, it can be difficult for
oncologists to make informed decisions about which
anticoagulant and treatment regimen would be of most
benefit to their patients.
Choosing the appropriate thromboprophylactic agent
The principal role of the antithrombotics in surgical
patients is to provide effective anticoagulation over the
course of the increased risk of VTE (during and post-
surgery) with the minimum of adverse events such as
post-operative bleeding. For cancer patients, there is
also increasing evidence that antithrombotics may pos-
sess anti-neoplastic effects and are potentially associated
with a reduced incidence of cancer and increased survi-
val times when given for long-term prophylaxis [32].
Such findings reinforce the importance of thrombopro-
phylaxis in oncology patients.
When deciding which drug to prescribe, each throm-
boprophylactic agent can be assessed in terms of three
main properties; their efficacy and safety profiles, practi-
cality of use, and cost-effectiveness. The relative merits
of the major anticoagulants according to these criteria,
as well as any possible anti-neoplastic effects are dis-
cussed below.
Efficacy and safety profiles
Primary prophylaxis
A meta-analysis of historical studies performed before
thromboprophylaxis was routinely prescribed, demon-
strated that low-dose unfractionated heparin (UFH) sig-
nificantly reduced the risk of combined symptomatic
and asymptomatic DVT compared with no prophylaxis
(8.7% vs. 25.2%; p < 0.001) in patients undergoing mod-
erate- and high-risk general surgery, without increasing
major bleeding (0.33% vs. 0.33%; p = 0.99). In a sub-ana-
lysis limited to cancer patients, UFH reduced the
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Later meta-analyses comparing UFH and LMWHs have
shown that the LMWHs are at least as effective in the
primary prophylaxis of VTE after general surgery
[34-36] and more effective following major orthopedic
surgery [35,37], with comparable or reduced risk of
bleeding.
A systematic review of 26 randomized controlled trials
comprising 7,639 cancer surgery patients highlighted the
importance of post-operative thromboprophylaxis with
either UFH or LMWH in these high-risk patients. The
overall incidence of combined symptomatic and asymp-
tomatic DVT was reduced from 35.2% in controls to
12.7% in those who received pharmacological prophy-
laxis [38]. However, few studies have directly compared
UFH and LMWH in cancer patients (Table 1) [39-45].
The Enoxaparin and Cancer (ENOXACAN) study
compared the LMWH enoxaparin and UFH in 1,115
patients undergoing abdominal or pelvic cancer surgery.
Enoxaparin (40 mg once daily [OD]) was associated with
a significantly lower rate of combined symptomatic and
asymptomatic VTE than UFH 5,000 IU three-times daily
(14.7% vs. 18.2%, respectively; 95% CI of the difference:
-9.2 to -2.3) without increasing the risk of major bleeding
(4.1% vs. 2.9%; p = not significant) [40]. A recent sys-
tematic review compared the outcomes in cancer patients
who received peri-operative thromboprophylaxis with
LMWH or UFH, and also found them to be comparable
in terms of efficacy (combined symptomatic and asymp-
tomatic DVT: relative risk [RR] 0.73; 95% CI: 0.23-2.28)
and safety (major bleeding: RR 0.95; 95% CI: 0.51-1.77).
However, in a post-hoc analysis of DVT incidence irre-
spective of diagnostic modality, LMWH was found to be
superior to UFH (DVT: RR 0.72; 95% CI: 0.55-0.94) [46].
The Pentasaccharide General Surgery Study (PEGA-
SUS) trial compared VTE prophylaxis following major
abdominal surgery (including cancer surgery) between
the synthetic pentasaccharide fondaparinux (2.5 mg
started 6 hours after surgery) and the LMWH dalteparin
started 2 hours before the operation (first two doses at
2,500 IU, and thereafter 5,000 IU daily). In a sub-group
analysis of cancer patients (n = 1,408) the combined
symptomatic and asymptomatic VTE rate was 4.7% with
fondaparinux compared with 7.7% in the dalteparin
group (RR reduction [RRR] 38.6%; 95% CI: 6.7-59.6).
The rate of major bleeding was not significantly differ-
ent (3.4% vs. 2.5%, respectively; p = 0.355) [44].
Overall, the available evidence indicates that thrombo-
prophylaxis significantly reduces the risk of VTE in can-
cer patients undergoing surgery, and that for primary
prophylaxis the LMWHs are at least comparable to
UFH in terms of efficacy and safety. There are currently
limited data directly comparing LMWH with fondapari-
nux in cancer patients.
Extended-duration primary thromboprophylaxis
Increased risk of VTE following major surgery has been
shown to extend for several weeks post-operatively
[4,47,48]. The prospective, observational @RISTOS pro-
ject evaluated the incidence and timings of clinically
overt VTE across a wide spectrum of patients under-
going cancer surgery. The study reported that the mean
time to VTE following cancer surgery was 17.2 days
(range, 2-58), with 40% of cases occurring more than 21
days post-operatively. However, these timings exceed
the standard duration of prophylaxis which has histori-
cally been limited to inpatient therapy. Accordingly, can-
cer surgery patients receiving only inpatient
thromboprophylaxis may be at risk of late VTE events.
In the @RISTOS project, 81.7% of cancer surgery
patients received in-hospital thromboprophylaxis,
whereas only 30.7% continued to receive prophylaxis fol-
lowing discharge [4].
There is considerable evidence to suggest that
extended-duration thromboprophylaxis may benefit can-
cer patients (Table 2) [48-50]. The ENOXACAN II
study demonstrated that extended-duration prophylaxis
with the LMWH enoxaparin (40 mg OD for 27-31 days)
significantly reduced the combined incidence of sympto-
matic and asymptomatic VTE in cancer patients under-
going abdominal surgery compared with those receiving
enoxaparin 40 mg OD for a standard duration of 6-10
days (4.8% vs. 12.0%, respectively; p = 0.02) without
increasing bleeding complications (6.1% vs. 4.8%; p =
not significant) [48]. The Fragmin After Major Abdom-
inal Surgery (FAME) study of the LMWH dalteparin,
which comprised 400 surgical patients of whom
approximately half underwent surgery for malignancy,
demonstrated that extending the duration of prophylaxis
from 1-4 weeks significantly reduced the incidence of
VTE without increasing bleeding [49]. In a sub-analysis
of cancer patients from this study, extended-duration
dalteparin significantly reduced the rate of combined
symptomatic and asymptomatic VTE at 4 weeks com-
pared with placebo (8.8% vs. 19.6%, respectively; RRR
55%; p = 0.03) [50]. Taken together, these data confirm
that extended-duration prophylaxis reduces VTE in this
high-risk population.
Prophylaxis in medical cancer inpatients
T h e r ei sag r o w i n ga w a r e n e s so ft h er i s k so fV T Ei n
hospitalized medical patients. Medical patients account
for approximately 60% of all hospital admissions and an
estimated 50-70% of all symptomatic inpatient VTE
events and 70% of all fatal PE events occur in medical,
rather than surgical patients [51]. Hospitalization for
non-surgical reasons is in itself a risk factor for VTE
and the presence of cancer, and its corollary risk factors,
further compounds the risk of developing a VTE event
[11]. Accordingly, guidelines include recommendations
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patients [1,16-19]. However, in the Fundamental
Research in Oncology and Thrombosis (FRONTLINE)
survey only 5% of medical oncologists reported that they
routinely used VTE prophylaxis in their cancer patients
[52].
Trials investigating thromboprophylaxis in medical
patients hospitalized for acute medical illnesses have
reported clinical benefits in terms of a significant reduc-
tion in VTE without increasing the rates of major
bleeding [53-55]. In the Prophylaxis in Medical Patients
with Enoxaparin (MEDENOX) study, the use of the
LMWH enoxaparin (40 mg subcutaneous [SC] OD) for
6-14 days significantly reduced the incidence of com-
bined symptomatic and asymptomatic VTE compared
with placebo (5.5% vs. 14.9%, respectively; RR 0.37;
97.6% CI: 0.22-0.63; p < 0.001). Major bleeding occurred
in 1.7% of patients treated with enoxaparin compared
with 1.1% in the placebo group [53]. In a sub-group
analysis of patients that had active or previously
Table 1 Summary of VTE and Major Bleeding Rates in Trials Comparing Primary Thromboprophylaxis Strategies in
Cancer Patients
Ref. Cancer Patients,
N
Drug VTE Detection VTE,
%
Bleeding*, %
Abdominal,
thoracic
241 Orgaran 750
IU BID
Asymptomatic VTE:
125I-fibrinogen and venography.
Symptomatic VTE: DVT - venography; PE - chest X-ray, VPS
10.4 9.0 (overall)
249 UFH 5,000 U
BID
14.9 10.6 (overall)
Abdominal,
pelvic
312 Enoxaparin 40
mg SC
Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS,
pulmonary angiography
14.7 14.6 (minor)
4.1 (major)
319 UFH 5,000 IU
SC TID
18.2 14.3 (minor)
2.9 (major)
Gynecological 160 Embolex
3,000 IU OD
Asymptomatic VTE: impedance plethysmography, phlebography 6.3 16.9 (wound
hematoma)
164 UFH 5,000 IU
TID
6.1 28.7 (wound
hematoma)
Gynecological 47 Enoxaparin
2,500 IU OD
Symptomatic VTE: DVT - ultrasonography, venography; PE - VPS,
pulmonary anteriography
None No significant
difference (rates not
given)
55 UFH 5,000 IU
TID
None
Colorectal (all
patients)
†
674 Enoxaparin 40
mg SC OD
Symptomatic and asymptomatic VTE: DVT - ultrasonography,
venography; PE - VPS, ultrasonography, venography, pulmonary
angiography
9.4 10.1 (total) 2.7
(major)
675 UFH 5,000 IU
SC TID
9.4 6.2 (total) 1.5
(major)
Cancer sub-
group
241 Enoxaparin 40
mg SC OD
13.9 Not reported
234 UFH 5,000 IU
SC TID
16.9
Abdominal
(all patients)
†
1,425 Dalteparin
5,000 IU OD
Symptomatic and asymptomatic VTE: DVT - ultrasonography,
venography; PE - lung scan, pulmonary angiography, helical
computed tomography, autopsy
6.1 2.5 (major)
1,433 Fondaparinux
2.5 mg SC OD
4.6 3.4 (major)
Cancer sub-
group
712 Dalteparin
5,000 IU OD
7.7 Not reported
696 Fondaparinux
2.5 mg SC OD
4.7
Colorectal 486 Enoxaparin 40
mg SC OD
Symptomatic and asymptomatic VTE: DVT - ultrasonography,
venography; PE pulmonary angiography, autopsy
12.6 11.5 (major)
464 Nadroparin
2,850 IU OD
15.9 7.3 (major)
BID, twice daily; DVT, deep vein thrombosis; OD, once daily; PE, pulmonary embolism; SC, subcutaneous; TID, three times daily; VPS; ventilation perfusion scan;
VTE, venous thromboembolism; UFH, unfractionated heparin.
*For definitions of major bleeding see original studies.
†Included non-cancer patients.
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placebo group compared with 9.7% (3/31) in those trea-
ted with enoxaparin (RR 0.50; 95% CI: 0.14-1.72; p =
0.4) [56].
Likewise in the Prospective Evaluation of Dalteparin
Efficacy for Prevention of VTE in Immobilized Patients
Trial (PREVENT), which included 3,706 medical inpati-
ents, of which 190 had cancer, the use of dalteparin
(5,000 IU SC OD) for 14 days reduced the combined
incidence of symptomatic and asymptomatic VTE from
4.96% in the placebo group to 2.77% (RR 0.55; 95% CI:
0.38-0.80; p = 0.0015). Major bleeding was not signifi-
cantly increased in the dalteparin group compared with
placebo (0.49% vs. 0.16%, respectively; p = 0.15) [54].
In the Arixtra for Thromboembolism Prevention in a
Medical Indications Study (ARTEMIS), 849 medical
inpatients were randomized to receive fondaparinux (2.5
mg SC OD) or placebo for 6-14 days [55]. In patients
with previous or current cancer VTE occurred in 17%
(95% CI: 7.6-30.8) of the fondaparinux group compared
to 3.9% (95% CI: 0.5-13.5) of the placebo group [57].
However, it should be noted that in all these trials can-
cer patients represented a sub-group of the total medical
patients enrolled and accordingly any conclusions based
on these data should reflect the relatively small sample
sizes.
Whilst guidelines delineate the appropriate clinical
responses for medical inpatients bedridden with cancer
or cancer patients hospitalized for a medical illness, they
are less clear regarding ambulatory outpatients, and
patients receiving highly thrombogenic chemotherapy.
For instance, the American College of Chest Physicians
(ACCP) guidelines recommend that all cancer patients
bedridden with an acute medical illness receive throm-
boprophylaxis (Grade 1A), but caution against routine
thromboprophylaxis in medical patients receiving che-
motherapy (Grade 1 C) [1]. Similarly, the American
Society of Clinical Oncology (ASCO) guidelines advo-
cate that all hospitalized cancer patients receive throm-
boprophylaxis, but recommend against routine
thromboprophylaxis in ambulant cancer patients receiv-
ing chemotherapy [17]. The ASCO guidelines also
recommend that ambulant patients receiving thalido-
mide or lenalidomide with chemotherapy or dexametha-
sone receive thromboprophylaxis with a VKA targeted
to an INR of 1.5 [17]. The Italian Association of Medical
Oncology (AIOM) recommend that hospitalized cancer
patients confined to bed receive thromboprophylaxis
with a LMWH (Level of evidence (LOE) I, Grade A),
but do not recommend routine prophylaxis in advanced
cancer patients receiving chemotherapy (LOE II, Grade
B) or in ambulatory cancer patients receiving adjuvant
chemotherapy or hormone therapy (LOE I, Grade A)
[16]. In contrast, the National Comprehensive Cancer
Network (NCCN) guidelines recommend that patients
on highly thrombogenic chemotherapy be considered
for thromboprophylaxis, but do not specify the preferred
pharmacotherapeutic strategy [19].
Recently, risk assessment models (RAMs) have been
developed specifically for VTE risk in cancer patients
Table 2 Summary of VTE and Major Bleeding Rates in Trials Comparing Extended-Duration Thromboprophylaxis
Strategies in Cancer Patients
Ref. Cancer Patients,
N
Drug VTE Detection VTE, % Bleeding*,
%
Gastrointestinal,
genitourinary,
gynecological
167 Enoxaparin 40 mg SC 6–10
days plus placebo 19–21 days
Symptomatic and asymptomatic VTE: DVT -
venography; PE - VPS, pulmonary angiography
12 3.6 (minor)
3.6 (major)
165 Enoxaparin 40 mg SC 25–31
days
4.8 4.7 (minor)
5.1 (major)
Abdominal (all
patients)
†
178 Dalteparin 5,000 IU OD plus
GCS for 7 days
Symptomatic and asymptomatic VTE: DVT -
venography; PE - VPS, spiral computerized
tomography, autopsy
16.3 0.9 (minor)
1.8 (major)
165 Dalteparin 5,000 IU SC OD plus
GCS for 7 days, plus further 21
days
7.3 1.5 (minor)
0.5 (major)
Abdominal cancer
sub-group
198 total Dalteparin 5,000 IU OD plus
GCS for 7 days
19.6
proximal
DVT: 10.4
Not
reported
Dalteparin 5,000 IU SC OD plus
GCS for 7 days, plus further 21
days
8.8
proximal
DVT: 2.2
DVT, deep vein thrombosis; GCS, graduated compression stockings; OD, once daily; PE, pulmonary embolism; SC, subcutaneous; VPS; ventilation perfusion scan;
VTE, venous thromboembolism.
* For definitions of major bleeding see original studies.
†Included non-cancer patients
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overall VTE risk score by ‘adding’ thrombogenic risk
factors from a variety of patient-, cancer- and treat-
ment-related factors including age, race and immobility
status, together with site or stage of the cancer, whether
or not the patient is receiving chemotherapy, presence
of biomarkers such as platelet count, tissue factor or D-
dimer levels [58-60]. These risk scores can aid in deter-
mining who is at risk of VTE and warrant
thromboprophylaxis.
Secondary/long-term prophylaxis
Guidelines recommend that the use of the oral anticoa-
gulant warfarin in cancer patients is limited to long-
term secondary prophylaxis following a VTE event or
for long-term anticoagulation [18,19]. The guidelines
note that cases of VTE should be initially treated with
either UFH or a LMWH [18,19], or LMWH [16,17]. In
a recent systematic review of the literature, the use of
LMWH over UFH for the initial treatment of VTE was
associated with significantly reduced mortality rates in
cancer patients (RR 0.71; 95% CI: 0.52-0.98) [61]. Data
on bleeding were unavailable for this analysis.
As a result of their suitability for outpatient use, the
LMWHs can also be considered for use in secondary/
long-term prophylaxis, a role traditionally performed by
warfarin. In a meta-analysis of studies investigating the
efficacy and safety of long-term treatment of VTE, the
LMWHs were associated with non-significant reductions
in the rates of recurrent symptomatic and asymptomatic
VTE (odds ratio [OR] 0.66; 95% CI: 0.41-1.07) and
major bleeding (OR 0.45; 95% CI: 0.18-1.11) compared
with oral anticoagulants [62]. In cancer patients, treat-
ment of VTE with the LMWH dalteparin was associated
with a lower rate of symptomatic, objectively confirmed
recurrent thromboembolismc o m p a r e dw i t hw a r f a r i n
(8.0% vs. 15.8%, respectively; hazard ratio [HR] 0.48; p =
0.002), without increasing the rate of major bleeding
(6% vs. 4%) or any bleeding (14% vs. 19%) [63]. Similar
findings were reported in a study comparing long-term
treatment with the LMWH tinzaparin with warfarin; 7%
of patients treated with tinzaparin and 16% of those
treated with warfarin experienced symptomatic, objec-
tively confirmed recurrent VTE (RR 0.44; 95% CI: -21.7
to -0.7; p = 0.044) [64]. Bleeding, which was largely
minor, occurred in 27% of patients receiving tinzaparin
and 24% receiving warfarin (absolute difference -3.0;
95% CI: -9.1 to 15.1).
A recent systemic review concluded that LMWHs for
long-term treatment of VTE in patients with cancer
reduce VTE compared with warfarin (HR 0.47; 95% CI:
0.32-0.71) [65]. There was no statistically significant dif-
ference between the LMWHs and warfarin in bleeding
outcomes in this study (RR 0.91; 95% CI: 0.64-1.31). On
the strength of these findings the available guidelines
increasingly recommend the LMWHs over warfarin for
VTE treatment [16-19].
Practicality of use
The use of UFH is complicated by its narrow therapeu-
tic range, resulting in frequent monitoring of activated
partial thromboplastin time or anti-Xa levels, and dose
adjustments may be required during treatment [66].
UFH has sub-optimal bioavailability and accordingly
when it is given subcutaneously it requires much larger
doses than when given intravenously to achieve equiva-
lent anticoagulation levels [67]. The heterogonous
assortment of molecules that make up UFH result in a
highly polygamous mixture capable of binding multiple
plasma proteins, macrophages, and endothelial cells
[68]. Accordingly, resulting anticoagulation responses to
UFH can vary widely. In contrast, the LMWHs have
higher bioavailability [69] and, because of their reduced
plasma protein binding, have a more predictable phar-
macokinetic profile [70] and a longer half-life [68].
Unlike UFH which is hepatically cleared, the LMWHs
are renally excreted. As such, monitoring may be
required in certain patient populations, including the
morbidly obese, those with severe renal impairment, and
pregnant women [68]. However, in the majority of
patients, the pharmacokinetic advantages of the
LMWHs mean they can be effectively administered
without the need to monitor the anticoagulant effect,
both in inpatient and outpatient settings.
Outpatient use
Although warfarin has historically been the mainstay of
long-term thromboprophylaxis, its use is complicated by
its narrow therapeutic window and the difficulty in
maintaining appropriate levels of anticoagulation [71].
Warfarin is affected by numerous interactions with a
wide-range of drugs, nutritional supplements and herbal
remedies, and its efficacy can be affected by vomiting
and diarrhea, all of which are common in cancer
patients. Intolerance, hypersensitivity, and resistance to
warfarin leading to treatment failure have all been
reported [71]. The effectiveness of warfarin is especially
compromised in cancer patients [72]. Compared with
matched controls, cancer patients on warfarin spent sig-
nificantly less time inside the target international nor-
malized ratio (INR) range (both supra- and sub-
therapeutic, 54% vs. 64%, respectively; p < 0.001), had
more variable INR values (p < 0.001), and had more
thrombotic events compared with matched non-cancer
patients (p < 0.001) [72]. Warfarin use in cancer patients
undergoing chemotherapy results in extra utilization of
hospital resources, especially through increased day vis-
its associated with warfarin monitoring and resulting
laboratory costs [73]. A further potential limitation of
warfarin therapy is that it has a slow onset and long
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represent a problem if anticoagulation needs to be inter-
rupted quickly for invasive procedures, as is frequently
the case in cancer patients.
The principal practical advantage of the LMWHs in
the outpatient setting, both for extended-duration pri-
mary prophylaxis and long-term secondary prophylaxis,
is the lack of a need to monitor anticoagulation in the
majority of patients. Patient compliance with LMWHs is
high in both non-cancer [75] and cancer populations
[76,77], with the majority of patients being comfortable
with self-administration. Outpatient thromboprophylaxis
in cancer patients with SC LMWH is associated with a
good safety profile and a high level of compliance [77].
In a study of VTE treatment in cancer patients, LMWH
was associated with improved quality-of-life over war-
farin, primarily on the basis of reduced blood tests and
increased optimism regarding therapy [78]. Similarly in
a pharmacoeconomic analysis using data from the Com-
parison of Low Molecular Weight Heparin Versus Oral
Anticoagulant Therapy for Long Term Anticoagulation
in Cancer Patients With Venous Thromboembolism
(CLOT) trial which compared the LMWH dalteparin
and warfarin for the long-term anticoagulation of cancer
patients with DVT, dalteparin was the preferred treat-
ment in 96% (23/24) of respondents and was associated
with a gain of 0.157 quality-adjusted life years (QALY)
[79].
Overall, therefore, LMWHs offer considerable advan-
tages over warfarin in cancer patients in terms of practi-
cality of use as well as in efficacy.
Cost comparisons
The costs involved in managing VTE in general are con-
siderable. In the US managing DVT alone is estimated
to cost around $1.5 billion annually [80]. The yearly
direct costs for treating an individual VTE episode are
high; $10,804 for a DVT event and $16,644 for a PE
event [81]. Furthermore, the long-term sequelae of VTE
such as post-thrombotic syndrome can further increase
costs [82]. Accordingly, the expenditure associated with
the provision of appropriate anticoagulation following
surgery can be offset by the savings achieved by averting
the costs of VTE management.
A number of studies have indicated that the LMWHs
are economically superior to UFH both for DVT treat-
ment [80,83,84], and for bridging to long-term anticoa-
gulation [85-87], and they are at least non-inferior or
superior to warfarin in preventing VTE following ortho-
pedic surgery [88,89]. However, there are limited data
regarding the economics associated with thrombopro-
phylaxis following cancer surgery. Data from the CLOT
trial on long-term prophylaxis in cancer patients with
DVT showed that overall costs were lower with warfarin
than dalteparin (CA $2,003 vs. $4,262, respectively; p <
0.001), primarily due to reduced drug-acquisition costs
[79]. However, when patient quality of life was also
included in the analysis dalteparin therapy was asso-
ciated with a cost of around CA $13,800 per QALY
gained [79], far below the $50,000 cost per QALY con-
sidered to be economically acceptable [90].
Anticoagulants may be associated with increased survival
in cancer patients
Three major studies have indicated that the LMWHs
may be associated with a survival benefit in cancer
patients that could not be directly linked to a reduction
in VTE incidence [91-93]. In the Malignancy and Low
Molecular Weight-Heparin Therapy (MALT) trial, can-
cer patients were randomly assigned to 6-weeks of either
the LMWH nadroparin (n = 148) or placebo (n =1 5 4 ) .
At 12 months the overall HR for death was 0.75 (95%
CI: 0.59-0.96) with a median survival of 8.0 months in
the nadroparin group compared with 6.6 months in the
placebo group [91]. Similarly, The Fragmin Advanced
Malignancy Outcome Study (FAMOUS) compared the
LMWH dalteparin given for 1-year with placebo in can-
cer patients. The Kaplan-Meier survival estimates for 1,
2, and 3 years after randomization were not different
between the dalteparin and placebo groups (p = 0.19).
However, in an analysis not planned ap r i o r i ,as u b -
group of patients who were alive at 17 months, experi-
enced significantly improved survival estimates at 2- and
3-years following randomization with dalteparin versus
placebo (78% vs. 55% and 60% vs. 36%, respectively; p =
0.03) with no increase in major bleeding rates [92].
Notably, these effects were observed long after dalte-
parin was discontinued, suggesting the survival benefit is
not dependent on VTE prophylaxis.
In the CLOT trial, over 600 patients with cancer and
VTE were randomized to receive 6-months of warfarin
or dalteparin therapy. A survival benefit for LMWH
over warfarin was observed in patients with non-meta-
static cancer, with a 20% mortality rate in the dalteparin
group compared with 36% with warfarin (HR 0.50; 95%
CI: 0.27-0.95; p = 0.03). However this benefit was not
maintained in patients with metastatic cancer (72% vs.
69%, respectively; HR 1.1; 95% CI: 0.87-1.4; p = 0.46)
[93].
Although some studies have suggested that warfarin
may also improve survival in cancer patients [94,95] and
reduce the incidence of cancer [96], a meta-analysis of
11 studies comparing mortality with the LMWHs versus
warfarin demonstrated that although the LMWHs
increased survival (RR 0.877; 95% CI: 0.789-0.975; p =
0.015) warfarin did not (RR 0.942; 95% CI: 0.854-1.040;
p = 0.239) [32]. Furthermore, patients receiving warfarin
therapy also had a significant increase in the risk of
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0.0001) whereas those receiving LMWH did not (RR
1.678; 95% CI: 0.861-2.269, p = 0.128). In a systematic
review of the literature, heparin (UFH or LMWH) was
associated with a survival benefit in cancer patients (HR
0.77, 95% CI 0.65-0.91) without significantly increasing
the risk of bleeding (RR 1.78, 95% CI 0.73-4.38) [97].
When analyzed by subgroups however, a statistically sig-
nificant survival benefit was observed in patients with
limited small-cell lung cancer (SCLC) (HR 0.56, 95% CI
0.38-0.83), but was not seen in patients with more
extensive SCLC (HR 0.80, 95% CI 0.60-1.06) or patients
with advanced disease (HR 0.84, 95% CI 0.68-1.03) [97].
Thus it appears that the LMWHs may be associated
with improved survival in certain cancer populations.
However, more studies are needed to fully characterize
this effect and how it is affected by different cancer
locations, types, and disease stage. Accordingly, current
evidence-based guidelines delineating appropriate
thromboprophylaxis and VTE-treatment in cancer
patients do not recommend the use of primary throm-
boprophylaxis to try to improve survival in cancer
patients, and use of a LMWH for this indication would
be off-label [1,17,19].
Findings suggest that the improvements in survival
seen with the LMWHs in cancer patients do not simply
result from a decrease in the incidence of VTE, but also
from potential anti-neoplastic properties of heparins.
Heparin and its derivatives possess mucopolysaccharide
chains similar to cell-surface and extra-cellular matrix
molecules, raising the possibility that UFH and LMWHs
can modulate how cells interact with their environment,
enzymes, and cell-signaling molecules, and so affect
malignant cell growth [98]. In vivo evidence suggests
that the anti-metastatic effects of heparins depend upon
P-selectin-mediated binding via their polysaccharide
chains rather than their antithrombotic activity [99].
Accordingly fondaparinux, which lacks a polysaccharide
chain, did not inhibit metastasis at clinically relevant
anticoagulation levels in this model [99]. Similarly, UFH,
LMWHs and oligosaccharide truncates of heparin have
been shown to inhibit tumor growth and metastasis in
vivo [100].
Heparin and oligosaccharide truncates of heparin have
also been shown to inhibit angiogenesis [101]. Studies
have demonstrated UFH and LMWH have dose-depen-
dent antiangiogenic effects that are mediated via release
of endothelial tissue factor pathway inhibitor, which are
independent of their antithrombotic activity [102].
Furthermore, heparins can directly affect the immune
system by their inhibitory effects on extravasation of
leukocytes and the complement system, or by enhancing
the susceptibility of cancer cells to immunologic attacks
[103]. Consequently, it is likely the proposed anti-
neoplastic effects of heparin and the LMWHs are a
combination of direct anti-neoplastic, antiangiogenetic,
and immunomodulatory effects, as well as indirect
effects resulting from their pleiotropic action on the
coagulation system.
Each LMWH has a particular structural profile which
in turns gives it specific pharmacokinetic and pharmaco-
dynamic properties [104,105]. Structural differences
between the LMWHs such as in the molecular weight,
molecule length, end-group composition, carboxyl-to-
sulfate group ratio and the proportion of anti-Xa bind-
ing domains have been shown to affect the biological
activity of the resulting molecule [104,105]. It is possible
therefore that the LMWHs possess different anti-meta-
static properties to one another. However, it is unclear
at present to what extent the structural heterogeneity
between the LMWHs translates into clinical differences
in the drug’s anti-metastatic effect. Current research is
investigating separating the anticoagulant and anti-meta-
static properties of heparin molecules for use in cancer
patients [106].
The complex mechanisms associated with improve-
ments in survival of cancer patients treated with hepar-
ins are of relevance to the new generation of oral
anticoagulants which are under development [107]. In
an attempt to separate antithrombotic and bleeding
effects, agents have been designed to inhibit specific
proteins within the coagulation cascade. However, these
new drugs lack the polypharmacological actions of the
UFH and LMWHs which are thought to be involved in
anti-neoplastic effects, and accordingly it is likely that
they will also have concurrent reductions in their anti-
neoplastic activity.
Discussion
Whilst heparin and vitamin K antagonists have been the
mainstay of anticoagulant therapy for over fifty years, a
new generation of anticoagulants are either recently
available or are currently under development, which
offer potential benefits over existing therapies in cancer
patients [108,109]. For instance, as cancer patients are at
an increased risk both of VTE and bleeding [30,31], can-
cer patients would benefit from anticoagulants that have
a favorable balance of anticoagulation to hemorrhagic
effects. AVE5026 is a new ultra low-weight LMWH in
development whose favorable safety-to-efficacy ratio
m a ym a k ei tp a r t i c u l a r l ys u i t a b l ef o rac a n c e rs e t t i n g
[110]. Some of the new anticoagulants, such as dabiga-
tran [111] and rivaroxaban [112,113], are orally adminis-
tered drugs that have proven effective in reducing the
incidence of VTE following major orthopedic surgery.
Whilst these new drugs are of potential interest in can-
cer because they don’t require laboratory monitoring
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tested in an oncology setting.
It is important to remember that the cancer popula-
tions discussed in the manuscript frequently comprise
heterogeneous patient groups. The mortality rate and
risk of VTE in one cancer population may not be
equivalent to another population, and likewise the risks
and benefits of particular anticoagulation therapies may
not necessarily the same either. Furthermore, as patients
with advanced cancer, renal or hepatic impairment, or
with a short-term prognosis are frequently excluded
from clinical trials, the patients included in clinical trials
are typically in better health than cancer patients seen
in clinical practice.
Conclusion
Cancer patients are at increased risk of VTE due to a
range of disease-, treatment- and patient-related factors.
Current evidence-based guidelines support the use of
anticoagulation in at-risk surgical cancer patients,
although generally there is limited specific guidance as
to which anticoagulant is most appropriate, or for how
l o n gt r e a t m e n ts h o u l db eg i v e n .B o t hU F Ha n dt h e
LMWHs are recommended for primary prophylaxis fol-
lowing cancer surgery. Studies show that the LMWHs
are at least as effective as UFH in this setting, but are
associated with a tendency towards lower bleeding.
Given the period of post-operative VTE risk, data
increasingly support extended-duration prophylaxis
beyond the period of hospitalization. The practical and
pharmacokinetic advantages of the LMWHs facilitate
such treatment, and the use of LMWHs in this setting
is associated with reduced hospital visits and a reduced
need for blood tests/monitoring. In other patient popu-
lations these advantages mean that the LMWHs are a
more cost-effective drug class than UFH, but more spe-
cific oncology-based studies are needed before this find-
ing can be applied to cancer patients.
The LMWHs are also recommended for use in sec-
ondary/long-term prophylaxis where, compared with
warfarin, they display increased efficacy with a good
safety profile and reliability, and are associated with
increased quality of life. In addition, the LMWHs have
been associated with a potential anti-neoplastic effects
which may contribute to improved survival times in
cancer patients. However, more studies are needed to
understand this effect, and the potential role of the
LMWHs as antineoplastic therapy.
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